In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: ...

Please provide your email address to receive an email when new articles are posted on . NT-proBNP may predict CV death, incident HF and fatal or nonfatal CV events after acute MI. The association was ...

Please provide your email address to receive an email when new articles are posted on . Childhood cancer survivors with abnormal global longitudinal strain and NT-proBNP had increased cardiomyopathy ...

Keep reading to learn how biomarker-guided cardioprotection may improve heart outcomes during anthracycline cancer treatment.

Elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a key biomarker for diagnosing heart failure, show a nearly fourfold increased risk for atrial fibrillation (AF) in at-risk ...

The relationship between chronic health conditions and employment transitions among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...

RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...